Charleston, South Carolina, June 5, 2024 – John Kauwe Ph.D., a 2013 CCAD awardee shares how CCAD made a difference in his research career. Kauwe is the president of BYU-Hawaii and owner of Halia Therapeutics, a company that discovers and develops novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. Halia Therapeutics is launching a phase I trial this summer using the target identified by from his CCAD grant and the subsequent work.
New Vision Research Continues to Impact Research Through Seed Funding.
June 26, 2024